Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Angiolo Gadducci, Stefania Cosio & Andrea Riccardo Genazzani. (2007) Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. Expert Review of Endocrinology & Metabolism 2:2, pages 225-238.
Read now
Read now
Articles from other publishers (19)
Mariana Sousa Silva, Yasmim de Andrade Gomes, Mickael Laudrup de Sousa Cavalcante, Pedro Victor Nogueira Telles, Alda Cássia Alves da Silva, Juliana Soares Severo, Raisa de Oliveira Santos, Brenda Lois Barros dos Santos, Gisele Lopes Cavalcante, Cláudio Henrique Lima Rocha, Raimundo Campos Palheta-Junior, Rita de Cássia Meneses Oliveira, Rosimeire Ferreira dos Santos, João Paulo Jacob Sabino, Armenio Aguiar dos Santos & Moisés Tolentino. (2021) Exercise and pyridostigmine prevents gastric emptying delay and increase blood pressure and cisplatin-induced baroreflex sensitivity in rats. Life Sciences 267, pages 118972.
Crossref
Crossref
Kailun He, Zhuo Zhang, Wenbing Wang, Xiaoliang Zheng, Xiaoju Wang & Xingxian Zhang. (2020) Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. Bioorganic & Medicinal Chemistry Letters 30:12, pages 127167.
Crossref
Crossref
Jenny Leipert, Stefan Hammerschmidt & Christian Geßner. (2019) Medikamentöse Therapie des metastasierten nicht-kleinzelligen LungenkarzinomsDrug treatment of metastasized non-small cell lung cancer. Der Pneumologe 16:6, pages 397-409.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
495
547
.
An-Chi Tsai, Hui-Chen Pai, Chih-Ya Wang, Jing-Ping Liou, Che-Ming Teng, Jing-Chi Wang & Shiow-Lin Pan. (2014)
In vitro
and
in vivo
anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells
. British Journal of Pharmacology 171:1, pages 122-133.
Crossref
Crossref
Nicolas Molina-Prat, Alejandro Saint-Jean & Maite Sainz de la Maza. (2013) Author reply. Ophthalmology 120:5, pages 1104-1105.
Crossref
Crossref
Alejandro Saint-Jean, Maite Sainz de la Maza, Merce Morral, Josep Torras, Ramon Quintana, Juan Jose Molina & Nicolas Molina-Prat. (2012) Ocular Adverse Events of Systemic Inhibitors of the Epidermal Growth Factor Receptor: Report of 5 Cases. Ophthalmology 119:9, pages 1798-1802.
Crossref
Crossref
S. Osdoit, E. Wierzbicka & G. Guillet. (2011) Incapacité motrice et fasciite radiologique sous erlotinib. Annales de Dermatologie et de Vénéréologie 138:6-7, pages 494-498.
Crossref
Crossref
Deepinder Singh, Kevin Bylund & Yuhchyau Chen. 2011. Advances in Radiation Oncology in Lung Cancer. Advances in Radiation Oncology in Lung Cancer
793
808
.
Lauren Averett Byers, Banibrata Sen, Babita Saigal, Lixia Diao, Jing Wang, Meera Nanjundan, Tina Cascone, Gordon B. Mills, John V. Heymach & Faye M. Johnson. (2009) Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clinical Cancer Research 15:22, pages 6852-6861.
Crossref
Crossref
Joaquín Casal Rubio, S. Vázquez, F. Vázquez, M. Amenedo, J. L. Fírvida, J. R. Mel, G. Huidobro, E. Álvarez, M. Lázaro, G. Alonso & I. Fernández. (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology 64:2, pages 379-384.
Crossref
Crossref
Yu-Chieh Wang, Samuel K. Kulp, Dasheng Wang, Chih-Cheng Yang, Aaron M. Sargeant, Jui-Hsiang Hung, Yoko Kashida, Mamoru Yamaguchi, Geen-Dong Chang & Ching-Shih Chen. (2008) Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors. Cancer Research 68:8, pages 2820-2830.
Crossref
Crossref
C Massard, J-J Voigt, A Laplanche, S Culine, A Lortholary, R Bugat, C Theodore, F Priou, M-C Kaminsky, T Lesimple, X Pivot, B Coudert, J-Y Douillard, Y Merrouche & K Fizazi. (2007) Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?. British Journal of Cancer 97:7, pages 857-861.
Crossref
Crossref
G. M. Verkhivker. (2007) Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics. Bioinformatics 23:15, pages 1919-1926.
Crossref
Crossref
Anastassios V. Koutsopoulos, Dimitris Mavroudis, Konstantina I. Dambaki, John Souglakos, Eleni G. Tzortzaki, John Drositis, George S. Delides, Vassilis Georgoulias & Efstathios N. Stathopoulos. (2007) Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome. Lung Cancer 57:2, pages 193-200.
Crossref
Crossref
Iacopo Sardi, Duccio Cavalieri & Maura Massimino. (2007) Emerging Treatments and Gene Expression Profiling in High-Risk Medulloblastoma. Pediatric Drugs 9:2, pages 81-96.
Crossref
Crossref
Stefan Bonn, Saturnino Herrero, Christine B. Breitenlechner, Andrea Erlbruch, Wolf Lehmann, Richard A. Engh, Michael Gassel & Dirk Bossemeyer. (2006) Structural Analysis of Protein Kinase A Mutants with Rho-kinase Inhibitor Specificity. Journal of Biological Chemistry 281:34, pages 24818-24830.
Crossref
Crossref
Takeshi Shimamura, Hongbin Ji, Yuko Minami, Roman K. Thomas, April M. Lowell, Kinjal Shah, Heidi Greulich, Karen A. Glatt, Matthew Meyerson, Geoffrey I. Shapiro & Kwok-Kin Wong. (2006) Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272. Cancer Research 66:13, pages 6487-6491.
Crossref
Crossref
Robert H. Bradbury. 2007. Cancer. Cancer
1
17
.